2023年6月30日

剑桥,麻萨诸塞州,美国剑桥,质量和纽约,6月29日2023(全球通讯社)——黑钻石疗法,Inc .(纳斯达克:BDTX),肿瘤临床分期精密公司开发万能钥匙疗法这一目标家庭的致癌突变基因定义的癌症患者,今天宣布承销公开发行的定价在公开发行15000000股普通股的每股5.00美元的价格。黑钻石的总销售收入,在扣除承销折扣和佣金和费用,预计将达7500万美元。所有股票的发行由黑钻石销售。此外,黑钻石授予了承销商一个30天的选择权,购买一个额外的2250000股普通股。此次ipo预计将在7月5日左右完成2023,惯例成交条件。Piper桑德勒是作为唯一的book-running经理提供。Wedbush PacGrow充当lead manager提供的。提供的股票被黑钻石依照一个有效暂搁注册声明,曾向美国证券交易委员会(SEC) 11月14日,2022年,由美国证券交易委员会宣布有效11月22日,2022(文件号333 - 268341)。提供的是只有通过书面的说明书和招股说明书补充,形成一个注册声明的一部分。初步招股说明书补充和描述相关的条款提供提交给美国证券交易委员会(SEC)和美国证券交易委员会的网站www.sec.gov。 When available, copies of the final prospectus supplement relating to the offering may also be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Black Diamond Therapeutics Black Diamond Therapeutics is a clinical-stage precision oncology medicine company focused on the development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Black Diamond leverages a deep understanding of cancer genetics and onco-protein structure and function, to discover and develop innovative MasterKey therapies. The Company’s MasterKey therapies are designed to overcome resistance, minimize on-target, wild-type mediated toxicities, and be brain-penetrant to address significant unmet medical needs of patients with genetically defined cancers. The Company is advancing a robust pipeline with lead clinical-stage program BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive NSCLC and in GBM, and BDTX-4933, a program targeting RAF MasterKey mutations in solid tumors, as well as discovery-stage research programs. The Company’s proprietary MAP drug discovery engine is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data and validate MasterKey mutations. For more information, please visit www.blackdiamondtherapeutics.com . Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the timing of the closing of the offering. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Black Diamond’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC and in its subsequent filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Black Diamond undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contacts: